Payment overview · 2025
General Payments
$173.38
7 reported records · 2 companies
Healthcare provider profile · identity verified
Brittany Yvette Bailey, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · CHESAPEAKE, VA · NPI 1295370757
Verified facts
What the public records show
CMS Open Payments records show Brittany Yvette Bailey, NP received $173.38 in general payments during 2025 across 7 reported records.
Axsome Therapeutics, Inc. accounted for 50.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $87.48 | 50.5% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $85.90 | 49.5% | 4 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $173.38 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $87.48 | 3 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $85.90 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 399 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 250 | 45 |
| Gabapentin | Gabapentin | 245 | 40 |
| Losartan Potassium | Losartan Potassium | 173 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 155 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 150 | 22 |
| Furosemide | Furosemide | 146 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 28 |
| Levothyroxine Sodium | Levothyroxine Sodium | 112 | 20 |
| Sertraline Hcl | Sertraline Hcl | 111 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 13 |
| Mirtazapine | Mirtazapine | 102 | 13 |
| Potassium Chloride | Potassium Chloride | 102 | 21 |
| Eliquis | Apixaban | 98 | 21 |
| Trazodone Hcl | Trazodone Hcl | 92 | 17 |
| Famotidine | Famotidine | 91 | 19 |
| Lisinopril | Lisinopril | 91 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 16 |
| Latanoprost | Latanoprost | 82 | 19 |
| Levetiracetam | Levetiracetam | 82 | 12 |
| Carvedilol | Carvedilol | 80 | 13 |
| Montelukast Sodium | Montelukast Sodium | 78 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 12 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 67 | 15 |
| Omeprazole | Omeprazole | 67 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 62 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 12 |
| Chlorthalidone | Chlorthalidone | 59 | suppressed |
| Valsartan | Valsartan | 59 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 54 | 13 |
| Metformin Hcl Er | Metformin Hcl | 53 | 11 |
| Alendronate Sodium | Alendronate Sodium | 52 | 11 |
| Donepezil Hcl | Donepezil Hcl | 50 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 13 |
| Jardiance | Empagliflozin | 47 | suppressed |
| Meloxicam | Meloxicam | 47 | suppressed |
| Pregabalin | Pregabalin | 47 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 21 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 45 | 12 |
| Memantine Hcl | Memantine Hcl | 44 | 12 |
| Metformin Hcl | Metformin Hcl | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | suppressed |
| Glipizide | Glipizide | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 21 |
| Risperidone | Risperidone | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 16 |
| Oxycontin | Oxycodone Hcl | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 30 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 14 |
| Travoprost | Travoprost | 27 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Timolol Maleate | Timolol Maleate | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Trospium Chloride | Trospium Chloride | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 18 |
| Prednisolone Acetate | Prednisolone Acetate | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Mirabegron Er | Mirabegron | 19 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Letrozole | Letrozole | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 17 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 13 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $173.38 · 7 records | Axsome Therapeutics, Inc. | Auvelity, TRINTELLIX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error